https://www.selleckchem.com/products/g140.html
In this study, with an average follow-up time of 33 months, no adverse effects requiring discontinuation were observed in any patient. Anti-IL-1 therapy is effective and reliable in the treatment of colchicine-resistant chronic FMF arthritis. The efficacy of anti-IL-1 therapy was realized without concomitant disease-modifying antirheumatic drug therapy, despite the reduction in colchicine dose. Anti-IL-1 therapy is effective and reliable in the treatment of colchicine-resistant chronic FMF arthritis. The efficacy of anti-IL-1 therapy was r
Like
Comment
Share
